GoldenSite™

best-in-class therapies through
radically optimized protein conjugation
for next-generation treatments.

GoldenSite™

best-in-class therapies through
radically optimized protein conjugation
for next-generation treatments.

HOW IT WORKS
science

“Effective treatments that let
patients continue living their lives,
created by passionate people
through boundary-pushing science.”

HOW IT WORKS

science

Our unique differentiators:

GoldenSite™: Every site in a protein available for site-specific conjugation. Find your GoldenSite™ for best conjugate performance.

Perfect definition: Lighting-fast click-chemistry enables >99% conjugation at any site. Perfect homogeneity, perfect peace-of-mind.

Smart chemistry. Simple manufacturing: No catalyst, no enzyme needed. Simply purify, conjugate and done.

What we are aiming for:

our benefit for developers

Enhance your drugs therapeutic window through
site optimization that achieves unconjugated
antibody-like biophysical profiles, enabling
higher dosing with reduced toxicity.

De-risk clinical development with
conjugates showing no increased
hydrophobicity, self-interaction, or
polyreactivity compared to naked
antibodies – predicting superior
pharmacokinetics and safety.

Leverage AI-ready datasets from systematic
site profiling to predict optimal conjugation
positions for new targets and payloads.

our benefit for patients*

Experience reduced side effects from ADCs
designed with optimized conjugation
sites that minimize off-target toxicity
and treatment-related adverse events.

Receive more potent therapies as
improved therapeutic windows allow
physicians to administer higher,
more efficacious amounts without
increased safety concerns:

Stay on treatment longer with better-
tolerated therapies reducing the substantial
discontinuation rate seen with current ADCs
due to adverse events.

*Disclaimer: While our preclinical data strongly
suggests these patient advantages, VALANX techn-
ology has not yet entered clinical trials. These
benefits represent our scientific hypothesis based
on laboratory evidence and established ADC
development principles.

PEOPLE